.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Refining Treatment Approaches for HER2+ Breast Cancer

EP. 1: HR-/HER2+ Early Stage Breast Cancer: Standards of Care

January 20th 2021

EP. 2: Adjuvant Systemic Therapy Decision Factors

January 20th 2021

EP. 3: Adjuvant Systemic Therapy Data Updates

January 29th 2021

EP. 4: De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

January 29th 2021

EP. 5: Hormone Therapy in HER2+ Breast Cancer

February 5th 2021

EP. 6: Moving Metastatic Therapy to Early Stage Setting

February 5th 2021

EP. 7: Newly FDA Approved Therapies: R/R HER2+ MBC

February 12th 2021

EP. 8: Sequencing Therapy in R/R HER2+ MBC

February 12th 2021

EP. 9: Brain Metastases Therapy in Second-Line HER2+ MBC

February 19th 2021

EP. 10: Practical Advice for Toxicity Management in HER2+ MBC

February 19th 2021

EP. 11: Novel Agents for Late-Stage HER2+ MBC

February 26th 2021

EP. 12: Phase 3 FeDeriCa and PHranceSCa Trial Overviews

February 26th 2021

EP. 13: Decision Factors for SubQ Therapy and Unmet Needs

March 5th 2021